Company news

Share this article:
Azur Pharma has entered into an agreement with BioSante Pharmaceuticals to acquire US rights to Elestrin, a gel formulation of estradiol indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause, for $3.3 million. FDA approved Elestrin in December 2006, and the product is patented through June 2022.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.

AbbVie's files all-oral HCV drug with FDA

AbbVie's all-oral HCV treatment filed off six Phase-III trials spanning 25 countries and 2,300 patients

Rumor: Pfizer offered to buy AstraZeneca

The rumored $101 billion bid would give Pfizer a foothold in imuno-oncology and diabetes.